Aclaris Therapeutics (ACRS) opened Q1 2026 with revenue of about US$2.0 million and a basic EPS loss of roughly US$0.15 per share. Trailing twelve month figures show revenue of US$8.4 million and a cumulative basic EPS loss of around US$0.56. Over recent quarters, revenue has moved between US$1.3 million and US$3.3 million, while quarterly basic EPS losses have sat in a range of roughly US$0.12 to US$0.16 per share, keeping the focus squarely on how much further margins can be tightened to pull losses under control.
See our full analysis for Aclaris Therapeutics.With the latest numbers on the table, the next step is to see how this earnings profile lines up with the prevailing narratives around growth, risk, and profitability that investors tend to follow.
Curious how numbers become stories that shape markets? Explore Community Narratives
Losses Stay Heavy Around US$20 Million
- Net income loss in Q1 2026 was US$19.8 million, very similar to the US$19.8 million loss in Q4 2025, and the trailing twelve month loss stood at US$69.7 million.
- Bears point to the forecast that earnings could decline about 10.6% per year over the next three years, and the current figures line up with that concern:
- Quarterly losses have stayed in a band of roughly US$14.6 million to US$19.8 million across the last four reported quarters, and the five year trend shows losses increasing about 5.8% per year.
- On a trailing twelve month basis, the company is still unprofitable with a cumulative basic EPS loss of US$0.56 and net income loss of US$69.7 million, which heavily supports the bearish view that profitability is not close based on the provided data.
Revenue Forecasts Point To Approximately 59.6% Growth
- Revenue over the trailing twelve months was US$8.4 million, and revenue is projected to grow at about 59.6% per year according to the provided forecast information.
- Supporters of a more bullish angle highlight this strong revenue outlook, but the numbers show a mixed picture that investors need to weigh carefully:
- Quarterly revenue has moved between US$1.3 million and US$3.3 million over recent reports, so the forecasted 59.6% growth rate is being set against a relatively small current revenue base.
- The same dataset that points to strong revenue growth also flags that the company is expected to remain unprofitable over the next three years, creating a tension between the bullish focus on top line expansion and the bearish focus on continuing losses.
Valuation Rich Versus Peers On 6.6x P/B
- The stock trades on a P/B of 6.6x, compared with about 2.6x for the wider US Pharmaceuticals industry and 2.8x for peers, while the current share price is US$4.86.
- Critics highlight this P/B premium as a key risk, and the supplied figures help explain why valuation is such a talking point:
- Despite the higher multiple, the company is still unprofitable on a trailing twelve month basis with net income loss of US$69.7 million and no forecast of profitability within the next three years in the provided data.
- Recent shareholder dilution combined with a P/B more than twice the industry average suggests investors are paying a high price relative to book value even though earnings are forecast to decline about 10.6% per year, which reinforces the bearish concern on downside risk.
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Aclaris Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
With such mixed signals on growth, losses and valuation, it helps to look past the headlines, move quickly and weigh both sides of the story using the 1 key reward and 3 important warning signs.
See What Else Is Out There
Aclaris Therapeutics is still posting sizeable losses around US$20.0 million per quarter and carries a 6.6x P/B multiple. It is not forecast to reach profitability soon.
If you are concerned about paying up for ongoing losses, it may be useful to compare this profile with companies that appear cheaper on fundamentals using the 51 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com